GTAB B — Glycorex Transplantation AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK65.73m
- SEK63.36m
- SEK29.96m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 36.1 | 27 | 28.2 | 36.1 | 30 |
Cost of Revenue | |||||
Gross Profit | 36.2 | 24.6 | 24.9 | 31.5 | 26.9 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.6 | 34.7 | 40 | 44.4 | 60.2 |
Operating Profit | 7.5 | -7.72 | -11.8 | -8.31 | -30.3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 6.88 | -8.05 | -12.2 | -8.52 | -30.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6.91 | -8.04 | -12.2 | -8.58 | -30.4 |
Net Income Before Extraordinary Items | |||||
Net Income | 6.91 | -8.04 | -12.2 | -8.58 | -30.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6.91 | -8.04 | -12.2 | -8.58 | -30.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.099 | -0.103 | -0.166 | -0.116 | -0.243 |
Dividends per Share |